While everyone else is busy treating your symptoms, We Develop the Cures.

Over the past 15 years our research has established that infection by Calcifying Nanoparticles or CNPs (formerly called Nanobacteria) is the direct cause of calcified plaque in arteriosclerotic heart disease and coronary artery disease (CAD). CNP infection is also the cause of the inflammation, swelling and thrombosis in CAD. CNPs also cause pathological calcification and soft plaque in other arterial blood vessels as well as in the skin, kidney stones, gall stones, dental calculus, dental pulp stones, testicular stones, prostate stones, salivary gland stones, brain sand, pineal stones, breast calcification, cancer and arthritic joints.  Our nanobiotics are the only therapies clinically validated and shown to eradicate CNP infections as well as the asociated calcification, inflammation and amyloid plaque deposits. Since CNPs cause coronary artery disease plaque and heart attacks/strokes, this is important information that both you and your physician should know.

 

CNPs (Nanobacteria) are unique "non-living" disease-causing infectious pathogens, as are viruses and prions. CNPs cause many chronic diseases in many of our organ systems. As with viruses & prions, CNPs do not have to be "living" to cause diseases. CNPs can infect all tissues and organs. CNPs directly cause heart disease plaque to form in our coronary arteries and cause calcification on our heart valves. CNPs also directly form kidney stones, gallstones, the calcification in Interstitial Cystitis (IC), Benign Prostatic Hypertrophy (BPH) and the calcifications in Chronic Prostatitis. They are also linked in clinical studies to premature birth and miscarriage. CNPs are also implicated in the development of calcified plaques in vascular dementia, Alzheimer's Disease and the erosion of the myelin sheath covering of nerves in MS. Because CNPs can cause cellular apoptosis (cell death) even in our lymphocyte blood cells and can alter RNA & DNA replication, they are closely-linked with cancers as a well-established calcification marker in cancers.

CNPs are 25-200 nanometers (1 nanometer=1 billionth of a meter) in size, reproduce very slowly (every 3-6 days). These unique properties of nano-size and extremely slow growth make them undetectable using standard clinical microscopes and culture times. CNPs require 3 months to culture. Even after successful culturing, research-grade electron microscopes are required to observe them. Hospital labs & physicians have no way to detect them! Yet they are there, and have always been there causing pathological calcification, inflammation, plaques and scar tissue wherever found in the body.

CNPs are the toughest bugs ever found so far: nicknamed "Conan the Bacterium" by one researcher. Our immune defense system has no capability to kill or defeat CNP infections. Our best immune defense is to temporarily slow them down by walling-off the localized area of infection, like the walling-off of a cyst. Even when encased by our cyst, they just become semi-dormant and calcify. CNPs are so extremely small that our body does not even recognize them as pathogens. They attach to molecular calcium and trick our cell-wall defense mechanisms and are readily invited into our cells through calcium channels.....then they reek havoc inside the cell's nucleus and mitochondria: altering RNA & DNA replication, causing cell death (apoptosis) or uncontrolled cell-growth like cancers. CNPs utilize calcium and lipids (LDL & VLDL) from our bloodstream as their primary food source, oxidizing LDL & VLDL cholesterols. Reducing cholesterol levels does not affect CNPs, as there is always enough cholesterol present for their needs.

Our researchers discovered CNPs (aka Nanobacteria) and we either conducted, directed or collaborated in all CNP research at highly-respected research institutions such as Mayo Clinic, Cleveland Clinic, Baylor, UTMB, Stanford, Harvard, NASA-JSC, NASA-Astronaut Space Program, UCSF, UCLA and many others Worldwide. There are literally hundreds of published scientific & clinical research papers on CNPs. Nonetheless, because this science is highly esoteric to researchers in infectious disease, cardiology, nephrology & neurology, your non-researcher physician is most-likely unfamiliar with these published research papers. Since the research started in the late 1980's and has been continuously growing, your physician has probably heard the term "Nanobacteria", but that's most-likely the extent of their knowledge. To avoid embarrassing your doctor or catching them "off guard", YOU may have to print-out the research and share it with them if you want to discuss it with them.....

 NanobacTX - the first Nanobiotic

In late 1996, NanoBiotech Founder & Endovascular Researcher Gary S. Mezo invented NanobacTX, (Nanobac is short for "Nanobacteria" and TX is medical shorthand for "treatment"....therefore NanobacTX means Nanobacteria treatment) NanobacTX is designed specifically to eradicate calcified artery plaque in the coronary arteries and throughout the body. In the absence of coronary artery disease plaque....there is virtually no risk of a heart attack.

IN THE BLOOD SUPPLY TO THE HEART, the coronary vessels and heart's microvasculature, CNP-infected plaques ultimately worsen to become unstable plaque that ultimately ruptures like a pimple, causing a heart attack. "We know that 70% of heart attacks are caused by unstable plaque, so what we really need for our patients is a way to identify the plaque that turns evil and puts them at jeopardy.” says Mayo Clinic cardiology researcher Birgit Kantor, M.D., PhD. Calcified coronary artery plaque is eventually "vulnerable" and ready to rupture, meaning that the plaques burst open (like a cyst or pimple) from inflammation & pressure with the contents flying into the heart's coronary blood stream, or other blood vessels. Ruptured calcified plaque debris in the bloodstream starts an aggressive blood-clotting cascade of events that causes a heart attack, a stroke or even death. Coronary Artery Disease (CAD) is the #1 cause of death in Men and Women. Our NanobacTX is specifically designed to reverse heart disease and coronary arteriosclerosis.

NanobacTX is a patented non-prescription nanobiotic shown effective in treating CNP infection, arteriosclerotic plaque and pathological calcification. NanobacTX is shown in published clinical studies to cause regression of calcified arteriosclerotic plaque. Regression of plaque allows bloodflow to return to normal, thereby alleviating symptoms of coronary artery disease, markedly improving exercise capacity and functional ability and vascular flexibility. Improving arterial elasticity or reducing stiffness will reduce risk of hypertension and cardiovascular morbidity and mortality. In published clinical studies by cardiologists, 6-12 months of nightly NanobacTX showed reversal of heart disease via coronary artery plaque regression as well as physical and functional improvement of coronary artery disease (CAD). Many patients in the studies were able to reduce or completely eliminate their need for heart medications that were previously required. Exercise tolerance (capacity/ability) was greatly increased and anginal chest pain and many other symptoms of heart disease were either greatly reduced or eliminated.

Bench science and clinical research studies show that heart disease can be proactively reversed....preventing heart attacks & strokes. NanobacTX is specifically designed to eradicate the arteriosclerotic calcified coronary artery plaque that is commonly known as heart disease.

"I know of no other treatment that is so successful."-Cardiologist,  Stephen Sinatra, MD ("NanobacTX - Major Breakthrough in Arterial Health" - The Sinatra Report) 

To Order NanobacTX and read the published science/clinical trials, please visit the NanobacTX page.


 UROBAC - the second Nanobiotic

UROBAC is designed for urinary tract CNP infections: BPH, PKD, Chronic Prostatitis, Interstitial Cystitis, & Kidney Stones. UROBAC was shown in published urology research studies at Cleveland Clinic to be effective in the treatment of enlarged prostate/BPH and chronic prostatitis. Pain is eradicated and quality of life symptom scores improve dramatically. Top Urology researcher, Daniel Shoskes, MD (Cleveland Clinic) conducted the Chronic Prostatitis UROBAC Study that was published in the Journal of UROLOGY: “We treated a group of patients with prostatic stones and long-standing CP/CPPSIII symptoms unresponsive to conventional therapies with UROBAC designed to eliminate stone forming nanobacteria and found that 80% had a significant improvement in symptoms (and stones dissolved) after 3 months"...."the study population represented a truly hard-core group of patients in whom multiple previous therapies had failed, including antibiotics, phytotherapy, a-blockers, neuromuscular therapies and prostatic massage. A response of such magnitude even in an uncontrolled study is noteworthy in this patient population.”
To order UROBAC and review the published science & clinical trials, visit our UROBAC Page.

___________________________________________________________________________ 

Although NanoBiotech is not a charity, many that have been helped with NanobacTX & UROBAC have wanted to help our efforts by donating to our research:

↓ To donate to our research, enter the amount in $USD & click "Donate":